[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354946-105":59,"doc-detail-354946-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","machine-learning-in-biomarker-driven-precision-oncology-automated-immunohistochemistry-scoring-and-emerging-directions-in-genitourinary-cancers","Machine Learning in Biomarker-Driven Precision Oncology: Automated Immunohistochemistry Scoring and Emerging Directions in Genitourinary Cancers","","Immunohistochemistry (IHC) is central to diagnostic, prognostic, and predictive biomarker assessment, yet manual scoring is constrained by subjectivity and inter-observer differences. Machine learning (ML) within digital pathology enables pattern recognition from annotated datasets to automate quantification on whole-slide images. This review assesses ML-assisted IHC scoring across validated biomarkers and emerging prognostic and predictive targets in genitourinary (GU) tumors, covering current clinical markers and novel immune and molecular proteins. Key limitations include dataset scarcity, staining variability, and regulatory hurdles.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/machine-learning-in-biomarker-driven-precision-oncology-automated-immunohistochemistry-scoring-and-emerging-directions-in-genitourinary-cancers/354946/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/machine-learning-in-biomarker-driven-precision-oncology-automated-immunohistochemistry-scoring-and-emerging-directions-in-genitourinary-cancers/354946.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"Why is automated ML-assisted immunohistochemistry scoring important in precision oncology?","Question",{"text":112,"@type":113},"Automated ML scoring improves reproducibility over visual IHC by reducing subjectivity and inter-observer variability. It also supports scalable quantification on whole-slide images, which is valuable for biomarker-based treatment decisions.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which IHC biomarkers are covered as current applications?",{"text":117,"@type":113},"The review highlights ML-based scoring for routinely used biomarkers including ER/PR, HER2, mismatch repair (MMR) proteins, PD-L1, and Ki-67.",{"name":119,"@type":110,"acceptedAnswer":120},"What emerging genitourinary cancer biomarkers does the review discuss?",{"text":121,"@type":113},"It reports early evidence for ML quantification of markers such as androgen receptor (AR), PTEN, cytokeratins, Uroplakin II, Nectin-4, and immune checkpoint proteins, with links to clinical outcomes.",{"name":123,"@type":110,"acceptedAnswer":124},"What limitations must be addressed before clinical adoption?",{"text":125,"@type":113},"Major limitations include limited availability of training datasets, variability in staining protocols, and regulatory challenges that affect validation and broader implementation.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},354946,1790552750,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Review  \nMachine Learning in Biomarker-Driven Precision Oncology: Automated Immunohistochemistry Scoring and Emerging Directions in Genitourinary Cancers  \nMatthew Yap 1, Ioana-Maria Mihai 1,2 and Gang Wang 1,2, *  \nReceived: 14 December 2025  \nRevised: 3 January 2026  \nAccepted: 4 January 2026  \nPublished: 6 January 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T 1Z7, Canada  \n2 Pathology and Laboratory Medicine, BC Cancer, Vancouver, BC V5Z 4E6, Canada  \n* Correspondence: [gang.wang1@bccancer.bc.ca](gang.wang1@bccancer.bc.ca)  \nSimple Summary  \nImmunohistochemistry (IHC) is a common test used by pathologists to detect cancer biomarkers, which can help with diagnosis, prognosis, and treatment selection. However, IHC results can vary between laboratories and between observers. New digital pathology tools and artificial intelligence (AI), particularly machine learning (ML) techniques, can analyse stained tissue more consistently. This review gives an overview of how ML is being used to automate IHC scoring, first in well-studied biomarkers and then emerging biomarkers. This review then explores how these innovations can apply to genitourinary (GU) oncology, including prostate, renal, and bladder tumours, for which researchers have begun applying ML to new biomarkers that may predict outcomes or treatment response. ML use in IHC scoring is promising but requires more validation.  \nAbstract  \nImmunohistochemistry (IHC) is essential for diagnostic, prognostic, and predictive biomarker assessment in oncology, but manual interpretation is limited by subjectivity and inter-observer variability. Machine learning (ML), a computational subset of AI that allows algorithms to recognise patterns and learn from annotated datasets to make predictions or decisions, has led to advancements in digital pathology by supporting automated quantification of biomarker expression on whole-slide images (WSIs) . This review evaluates the role of ML-assisted IHC scoring in the transition from validated biomarkers to the discovery of emerging prognostic and predictive IHC biomarkers for genitourinary (GU) tumours. Current applications include ML-based scoring of routinely used biomarkers such as ER/PR, HER2, mismatch repair (MMR) proteins, PD-L1, and Ki-67, demonstrating improved consistency and scalability. Emerging studies in GU cancers show that algorithms can quantify markers including androgen receptor (AR), PTEN, cytokeratins, Uroplakin II, Nectin-4 and immune checkpoint proteins, with early evidence indicating associations between ML-derived metrics and clinical outcomes. Important limitations remain, including limited availability of training datasets, variability in staining protocols, and regulatory challenges. Overall, ML-assisted IHC scoring is a reproducible and evolving approach that may support biomarker discovery and enhance precision GU oncology.  \nKeywords: precision oncology; machine learning; digital pathology; artificial intelligence; immunohistochemistry; automation; prognostic; predictive; biomarker  \n1. Introduction  \nPrecision oncology depends on accurate biomarker detection and quantification to predict treatment response or determine patient eligibility for targeted therapies [1–3] . Immunohistochemistry (IHC) is traditionally assessed by visual scoring, which faces limitations in precision due to subjective threshold interpretation, inter-observer variability, and poor scalability [4–7] . Such constraints have inspired innovations in digital pathology and artificial intelligence (AI) to streamline clinical biomarker quantification [5,8] .  \nThough liquid biopsy assays such as those detecting circulating tumour DNA are gaining traction in real-time, prognostic detecti","cbCaiqakFFFQQX74","https://ap.wps.com/l/cbCaiqakFFFQQX74","pdf",383293,21,"English","# Simple Summary\n# Abstract\n# Keywords\n# 1. Introduction\n## Precision oncology and biomarker quantification\n## Limits of visual IHC scoring and need for automation\n## Role of liquid biopsy versus tissue-based IHC\n## Whole-slide imaging and ML-enabled IHC scoring\n## Translation toward GU oncology applications","[{\"question\":\"Why is automated ML-assisted immunohistochemistry scoring important in precision oncology?\",\"answer\":\"Automated ML scoring improves reproducibility over visual IHC by reducing subjectivity and inter-observer variability. It also supports scalable quantification on whole-slide images, which is valuable for biomarker-based treatment decisions.\"},{\"question\":\"Which IHC biomarkers are covered as current applications?\",\"answer\":\"The review highlights ML-based scoring for routinely used biomarkers including ER/PR, HER2, mismatch repair (MMR) proteins, PD-L1, and Ki-67.\"},{\"question\":\"What emerging genitourinary cancer biomarkers does the review discuss?\",\"answer\":\"It reports early evidence for ML quantification of markers such as androgen receptor (AR), PTEN, cytokeratins, Uroplakin II, Nectin-4, and immune checkpoint proteins, with links to clinical outcomes.\"},{\"question\":\"What limitations must be addressed before clinical adoption?\",\"answer\":\"Major limitations include limited availability of training datasets, variability in staining protocols, and regulatory challenges that affect validation and broader implementation.\"}]","Machine Learning in Biomarker-Driven Precision Oncology: Automated Immunohistochemistry Scoring and Emerging Directions in Genitourinary Cancers | PDF",1790114956,53,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/866ff59e459a59b456db01c6bd6ee45f.webp",983,1390,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/95a0235d996f3c63cbc8360ce1e308c7.webp",982,1388,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/edcc36c0bcf5b467ac7cec57d56224bb.webp",981,1387,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bcc865c7486ef7aac7845dfb5a7fe57d.webp",980,1385]